| Nov 11 |
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD)
|
| Nov 7 |
Prelude Therapeutics GAAP EPS of -$0.43, revenue of $3M
|
| Nov 6 |
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Oct 27 |
Prelude Therapeutics price target lowered to $1 from $3 at Barclays
|
| Oct 24 |
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
|
| Oct 9 |
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
|
| Sep 13 |
Prelude Therapeutics Says PRT3789 Shows 'Encouraging Signs' in Phase 1 Trial; Shares Fall
|
| Sep 13 |
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
|
| Sep 9 |
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
|
| Aug 29 |
MSD discontinues two Phase III Keytruda trials
|
